Content of review 1, reviewed on October 10, 2021

Remarks to the Author:
The authors have responded my concerns and revised the manuscript accordingly. I hope the authors will pay more attention to the data because this is what is being used to explain the results and also remember to minimize the bias in the future paper. I have no further major concerns.

Source

    © 2021 the Reviewer.

References

    Ulrik, P., M., A. R., B., B. J. M., C., A. A., U., A. H., Henning, B., Peter, G., K., H. T., Christoffer, H., J., J. T., B., J. C., K., J. A., S., L. S., Kirsten, N., Hans-Henrik, P., L., S. A., Lise, T., Birger, T. 2022. Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open-label, crossover trial. Diabetes, Obesity and Metabolism.